Efficacy of Pneumatic Retinopexy in Treating Rhegmatogenous Retinal Detachment at King Abdullah Medical City in Makkah, Saudi Arabia – A retrospective cohort study

Introduction: The aim of this study was to present the clinical presentation and short-term outcomes of uncomplicated rhegmatogenous retinal detachment managed by pneumatic retinopexy at a tertiary eye hospital in western Saudi Arabia. Materials and methods: This one-armed retrospective cohort study evaluated selected cases of rhegmatogenous retinal detachment managed by pneumatic retinopexy between 2017 and 2018. Data were collected on patient demographics, preoperative ophthalmic assessment, surgical details, follow up at six months postoperatively, complications and the need for additional surgery. Anatomic success was defined as retinal attachment at 6 months and functional success was defined as vision >20/200 at six months postoperatively. The association of lens status and concomitant laser treatment to anatomical success rates were evaluated. Results: The study sample consisted of 15 eyes with rhegmatogenous retinal detachment in the upper quadrant. In 14 cases, C3F8 gas was used. Anatomic and functional success was noted in 73.3% [95% confidence interval (CI) 51.0: 95.7] and 86.7% (95% CI 69.2; 100) of eyes, respectively. The association between anatomical success and lens status was not significant [RR = 4.5 (95% CI 0.6 ; 37.5), P=0.1]. There was no significant association between anatomical success and concomitant laser treatment. [RR = RR = 1.7 (95% CI 0.7 ; 4.0), P=0.2]. A 2nd retinal surgery was not required in 33.3% of eyes (95% CI 9.5 ; 57.2). Conclusion: If stringent selection criteria are used for managing rhegmatogenous retinal detachment with pneumatic retinopexy, anatomical and functional success by six months postoperatively is achieved in the majority of cases. Additional surgeries could further improve outcomes.

Download Full-text

PB2310 OUTPATIENT FOLLOW-UP IS ASSOCIATED WITH REDUCED EMERGENCY DEPARTMENT VISITS IN PATIENTS WITH SICKLE CELL DISEASE – A RETROSPECTIVE COHORT STUDY FROM RIYADH, SAUDI ARABIA

HemaSphere ◽

10.1097/01.hs9.0000567708.40912.cf ◽

2019 ◽

Vol 3 (S1) ◽

pp. 1030-1031

Author(s):

R. Saleh ◽

L. Alhmaly ◽

R. Vishwakarma ◽

I. Kamran ◽

M. Damlaj ◽

...

Keyword(s):

Emergency Department ◽

Saudi Arabia ◽

Cohort Study ◽

Sickle Cell Disease ◽

Sickle Cell ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Emergency Department Visits ◽

Cell Disease

Download Full-text

Clinical Significance of Co-expression of Aberrant Antigens in Acute Leukemia: A Retrospective Cohort Study in Makah Al Mukaramah, Saudi Arabia

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2014.15.1.221 ◽

2014 ◽

Vol 15 (1) ◽

pp. 221-227 ◽

Cited By ~ 8

Author(s):

Nahla Ahmad Bahgat Abdulateef ◽

Manar Mohammad Ismail ◽

Hanadi Aljedani

Keyword(s):

Saudi Arabia ◽

Cohort Study ◽

Acute Leukemia ◽

Clinical Significance ◽

Retrospective Cohort Study ◽

Retrospective Cohort

Download Full-text

Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study

Kidney & Blood Pressure Research ◽

10.1159/000510612 ◽

2020 ◽

Vol 45 (6) ◽

pp. 939-954

Author(s):

Abdulaziz A. Bamhraz ◽

Khawla A. Rahim ◽

Hassan Y. Faqeehi ◽

Abdulkarim Alanazi

Keyword(s):

Saudi Arabia ◽

Cohort Study ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Atypical Hemolytic Uremic Syndrome ◽

Renal Recovery ◽

Genetic Mutations ◽

Plasma Therapy ◽

High Prevalence ◽

Uremic Syndrome

Introduction: Genetic defects that determine uncontrolled activation of the alternative complement pathway have been well documented, which account for approximately 40–60% of atypical hemolytic uremic syndrome (aHUS) cases worldwide. In Saudi Arabia, nearly half of the marriages are consanguineous, resulting in a high prevalence of such genetic diseases. Recent studies have demonstrated the effectiveness of eculizumab against aHUS. Objective: We report our experience of using plasma therapy or/and eculizumab to treat children with aHUS in a tertiary care center in Saudi Arabia and to compare their clinical characteristics, genetic mutations, and treatment outcomes. Methods: A retrospective cohort study was conducted between January 2010 and May 2017. Data, including demographic parameters, clinical presentation, hospital stay duration, need for dialysis, renal recovery, genetic mutations, and outcomes, were obtained from electronic medical records of all eligible patients. Results: Overall, 21 children with aHUS were included, of which 12 (57.1%) received eculizumab therapy and 9 (42.9%) received only plasma therapy. End-stage renal disease occurred in 7 children (33.3%), of which 4 (57.1%) received only plasma therapy and 3 (42.9%) received eculizumab therapy whose genetic mutations were not related to the complement dysregulation system. No child who received eculizumab therapy showed recurrence; however, 3 children (33.3%) who received plasma therapy alone showed recurrence. Genetic mutations were detected in 12/20 (60%) of those who underwent genetic screening. Conclusions: Children who received eculizumab therapy showed good renal recovery and maintained remission compared with children who received plasma therapy alone. Genetic mutations were detected in 60% of the patients, which was associated with a high prevalence of consanguineous marriages.

Download Full-text